ZBIO
Zenas BioPharma, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.20B
P/E Ratio
—
EPS
$-9.10
Beta
—
52W High
$44.60
52W Low
$8.91
50-Day MA
$20.41
200-Day MA
$24.51
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-193.59M |
| EBITDA | $-251.37M |
| Operating Margin | 0.00% |
| Return on Equity | -137.10% |
| Return on Assets | -29.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.44 |
| Price-to-Book | 3.57 |
| Price-to-Sales (TTM) | 119.50 |
| EV/Revenue | 85.32 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $63.13M |
| Float | $39.68M |
| % Insiders | 23.20% |
| % Institutions | 94.28% |
Historical Volatility
HV 10-Day
92.67%
HV 20-Day
90.34%
HV 30-Day
79.89%
HV 60-Day
79.38%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($42.12 target)
7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026